Chromosome Disorders  >>  Tasigna (nilotinib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tasigna (nilotinib) / Novartis, Inhibikase
NCT00384228: A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL

Completed
1/2
42
Japan
Nilotinib, AMN107
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
01/07
 
NCT01602952: Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI

Completed
1/2
85
RoW
Radotinib, IY5511HCl
Il-Yang Pharm. Co., Ltd.
Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Philadelphia Chromosome, Hematologic Diseases
10/12
07/18

Download Options